Objective To observe the influence of atorvastatin combining Tongxinluo Capsules on hypertensive artery disease and left ventricular hypertrophy in patients with primary hypertension.Methods The patients (n=136) were chosen from Mar. 2013 to Sept. 2014, and randomly divided into Tongxinluo group (n=68, male 39 and female 29) treated with Tongxinluo Capsules and combined group (n=68, male 37 and female 31) treated with Tongxinluo Capsules and atorvastatin for 24w. The blood pressure (BP), EPFV, APFV and E/A were compared before and after treatment. The levels of LDL-C, HDL-C, TG, TC, ox-LDL and hs-CRP were detected, and changes of carotid artery intima-media thickness (CA-IMT) and in-artery atherosclerotic plaque area were compared before and after treatment.Resutls After treatment, 24h average systolic blood pressure and 24h average diastolic blood pressure decreased in 2 group (allP<0.01). The levels of LDL-C, TG, TC, ox-LDL and hs-CRP decreased and level of HDL-C increased in combined group compared with Tongxinluo group after treatment (all P<0.05). Compared with the same group, CA-IMT and in-artery atherosclerotic plaque area decreased significantly in 2 groups after treatment (allP<0.01). CA-IMT [(1.13±0.05) mmvs. (1.42±0.06) mm] and in-artery atherosclerotic plaque area [(0.41±0.02) cm2vs. (0.73±0.06) cm2] were significantly lower in combined group than those in Tongxinluo group (allP<0.05). After treatment, EPFV and E/A increased significantly and APFV decreased in 2 group (allP<0.01). Compared with Tongxinluo group, EPFV [(62.38±2.44) cm/svs. (69.10 ±1.97) cm/s] and E/A [(0.90±0.430vs. (1.18±0.27)] increased significantly and APFV decreased [(65.27±2.06) cm/svs. (60.73±2.28) cm/s] in combined group after treatment (allP<0.05).Conclusion Atorvastatin combining Tongxinluo Capsules is better than only Tongxinluo Capsules in treatment of vessel disease and left ventricular hypertrophy in hypertensive patients.%目的：观察阿托伐他汀联合通心络对原发性高血压患者动脉血管病变及左心室肥厚的影响。方法选择2013年3月~2014年9月间于首都医科大学附属复兴医院门诊收治的136例高血压患者。随机分为两组：通心络组（68例），男性39例，女性29例；联合用药组（68例），男性37例，女性31例。通心络组患者服用通心络胶囊；联合用药组患者服用通心络胶囊和阿托伐他汀，治疗周期为24周。比较治疗前后患者的血压、二尖瓣舒张早期血流峰值（EPFV）、晚期血流峰值（APFV）及其峰值比（E/A）；检测治疗前后低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、三酰甘油（TG）、总胆固醇（TC）、氧化修饰低密度脂蛋白（ox-LDL）和高敏C反应蛋白（hs-CRP）。比较颈动脉内膜-中膜厚度（IMT）以及动脉血管内粥样硬化斑块面积变化。结果与本组治疗前比较，通心络组和联合用药组治疗后24h平均收缩压以及24h平均舒张压均下降，差异有显著统计学意义（P均＜0.01）。与通心络组治疗后比较，联合用药组LDL-C、TG、TC、ox-LDL和hs-CRP均降低，HDL-C升高，差异有统计学意义（P均＜0.05）。与本组治疗前比较，通心络组和联合用药组治疗后的颈动脉IMT值及斑块面积均显著下降，差异具有显著统计学意义（P均＜0.01）。联合用药组治疗后IMT值及斑块面积显著低于通心络组，分别为（1.13±0.05）mmvs.（1.42±0.06）mm，（0.41±0.02）cm2vs.（0.73±0.06）cm2，差异有统计学意义（P均＜0.05）。与本组治疗前比较，通心络组和联合用药组治疗后EPFV和E/A均显著升高，APFV降低，差异具有显著统计学意义（P均＜0.01）。与通心络组比较，联合用药组治疗后EPFV和E/A均显著升高，APFV降低，数值为（62.38±2.44）cm/svs.（69.10±1.97）cm/s，（0.90±0.43）vs.（1.18±0.27），（65.27±2.06）cm/svs.（60.73±2.28）cm/s，差异具有统计学意义（P均＜0.05）。结论阿托伐他汀联合通心络治疗高血压患者的动脉血管病变及左心室肥厚效果优于单独应用通心络。
展开▼
